Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(applications tested for the base form of this product only)
Threonine187-phosphorylated p27 peptide derived from the C-terminus of the human p27 protein(1). This sequence differs by a single amino acid (not at the phosphorylated threonine) in the mouse, rat, and hamster p27 proteins.
Specific for the Thr-187 phosphorylated form of the cyclin-dependent kinase inhibitor p27KIP1. The antibody does not react with unphosphorylated p27 or with related CDK inhibitor proteins. This antibody can be used to detect endogenous phosphorylated-p27 by Western blotting if lysates are first immunoprecipitated with 'plain' p27 antibody e. g. Rb x p27, cat no. 71-9600 or Ms x p27, cat no.33-2800). Characterization of this antibody has been carried out primarily with purified recombinant p27 incubated in kinase reactions.
Suitable for use in ELISA, Western Blot and Immunoprecipitation. ELISA: 0.1-1.0 ug/ml. Milk-derived blocking solutions reportedly contain phosphoproteins that may inhibit phosphoamino acid antibody binding and therefore should be avoided. A 3% BSA. solution may also be used. Immunoprecipitation: 15 ug/IP reaction. Western Blot: 5-10 ug/ml.
PBS, pH 7.4, 0.05% Sodium Azide
Short term: 4°C; Long term: Add glycerol (40-50%) -20°C.
Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry.